1. Home
  2. ZLAB vs SPTN Comparison

ZLAB vs SPTN Comparison

Compare ZLAB & SPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • SPTN
  • Stock Information
  • Founded
  • ZLAB 2013
  • SPTN 1917
  • Country
  • ZLAB China
  • SPTN United States
  • Employees
  • ZLAB N/A
  • SPTN N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • SPTN Food Distributors
  • Sector
  • ZLAB Health Care
  • SPTN Consumer Discretionary
  • Exchange
  • ZLAB Nasdaq
  • SPTN Nasdaq
  • Market Cap
  • ZLAB 3.5B
  • SPTN N/A
  • IPO Year
  • ZLAB 2017
  • SPTN N/A
  • Fundamental
  • Price
  • ZLAB $29.48
  • SPTN $18.89
  • Analyst Decision
  • ZLAB Buy
  • SPTN Hold
  • Analyst Count
  • ZLAB 4
  • SPTN 1
  • Target Price
  • ZLAB $47.37
  • SPTN $20.00
  • AVG Volume (30 Days)
  • ZLAB 1.3M
  • SPTN 256.4K
  • Earning Date
  • ZLAB 05-08-2025
  • SPTN 05-29-2025
  • Dividend Yield
  • ZLAB N/A
  • SPTN 4.65%
  • EPS Growth
  • ZLAB N/A
  • SPTN N/A
  • EPS
  • ZLAB N/A
  • SPTN 0.01
  • Revenue
  • ZLAB $418,326,000.00
  • SPTN $9,549,324,000.00
  • Revenue This Year
  • ZLAB $44.43
  • SPTN $5.82
  • Revenue Next Year
  • ZLAB $48.68
  • SPTN N/A
  • P/E Ratio
  • ZLAB N/A
  • SPTN $2,137.45
  • Revenue Growth
  • ZLAB 43.72
  • SPTN N/A
  • 52 Week Low
  • ZLAB $15.65
  • SPTN $17.30
  • 52 Week High
  • ZLAB $39.77
  • SPTN $23.00
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 46.03
  • SPTN 45.46
  • Support Level
  • ZLAB $27.61
  • SPTN $18.59
  • Resistance Level
  • ZLAB $32.02
  • SPTN $20.23
  • Average True Range (ATR)
  • ZLAB 1.18
  • SPTN 0.45
  • MACD
  • ZLAB -0.13
  • SPTN -0.10
  • Stochastic Oscillator
  • ZLAB 35.72
  • SPTN 32.08

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Share on Social Networks: